{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:20Z","timestamp":1788498920632,"version":"build-2803163510"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>PI-RADS 3 lesions are equivocal on prostate MRI, complicating biopsy decisions. We aimed to develop and externally validate a simple pre-biopsy risk stratification model using routinely available clinical and MRI variables to guide selective biopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this multicenter retrospective study, men with PI-RADS 3 lesions undergoing transperineal biopsy at two tertiary hospitals (Jan 2023\u2013Dec 2025) were included. One center served as the development cohort and the other as external validation. Clinically significant prostate cancer (csPCa) was defined as ISUP Grade Group \u22652. Candidate predictors included age, abnormal digital rectal examination (DRE), PSA density (PSAD), lesion location, and maximum lesion diameter. A multivariable logistic regression model was developed and validated externally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 275 men (153 development, 122 validation), csPCa was detected in 37 (24.2%) and 31 (25.4%), respectively. PSAD and age were the main predictors, with other variables contributing to overall risk estimation. The model showed good discrimination (AUC 0.818 development, 0.846 validation), acceptable calibration, and decision curve analysis indicated potential clinical utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This preliminary model using routinely available clinical and MRI variables may support pre-biopsy risk stratification in men with PI-RADS 3 lesions. However, further validation in larger and more diverse cohorts is required before routine clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1864100","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:38Z","timestamp":1788495878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and external validation of a simple pre-biopsy risk stratification model for clinically significant prostate cancer in men with PI-RADS 3 lesions: a multicenter transperineal biopsy study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuhui","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Urology, Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Urology, Xiangtan Central Hospital (Hunan University Affiliated Hospital)","place":["Xiangtan, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"B3","volume-title":"Edn. Presented at the EAU Annual Congress London 2026","year":"2026"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00417-1","article-title":"Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level","volume":"25","author":"Oerther","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.08.009","article-title":"Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative","volume":"40","author":"Drevik","year":"2022","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl Androl Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-023-03929-7","article-title":"PI-RADS 3 lesions: a critical review and discussion of how to improve management","volume":"48","author":"Nicola","year":"2023","journal-title":"Abdom Radiol (NY)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","article-title":"Diagnostic performance of prostate-specific antigen density for detecting clinically significant prostate cancer in the era of magnetic resonance imaging: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2024","journal-title":"Br J Radiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216304","article-title":"Radiomics in PI-RADS 3 multiparametric MRI for prostate cancer identification: literature models re-implementation and proposal of a clinical-radiological model","volume":"11","author":"Corsi","year":"2022","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.825429","article-title":"Development and validation of a radiomics nomogram for predicting clinically significant prostate cancer in PI-RADS 3 lesions","volume":"11","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1247682","article-title":"Magnetic resonance imaging radiomics-based prediction of clinically significant prostate cancer in equivocal PI-RADS 3 lesions in the transitional zone","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5100","article-title":"Development and external validation of a novel nomogram to predict prostate cancer in biopsy-na\u00efve patients with PSA <10 ng\/ml and PI-RADS v2.1 = 3 lesions","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.62347\/XBBI9870","article-title":"Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging","volume":"14","author":"Liang","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040270","article-title":"Equivocal PI-RADS three lesions on prostate magnetic resonance imaging: risk stratification strategies to avoid MRI-targeted biopsies","volume":"10","author":"Osses","year":"2020","journal-title":"J Pers Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00872-6","article-title":"Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions","volume":"28","author":"Mjaess","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/03915603241286064","article-title":"Comparison of the incidence of clinically significant prostate cancer in patients with isolated peripheral versus transitional zone PI-RADS 3 lesions","volume":"92","author":"Malshy","year":"2025","journal-title":"Urologia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:39Z","timestamp":1788495879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":18,"alternative-id":["10.3389\/fonc.2026.1864100"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1864100","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1864100"}}